Recombinant Marek's Disease Virus Vectors for Multivalent Poultry Vaccines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current multivalent recombinant vaccines for poultry viruses, such as Marek's Disease, Newcastle Disease, and Infectious Laryngotracheitis, face instability and inefficacy due to complex interactions between insertion sites and foreign genes, leading to incomplete immune responses.
Innovation Solution
Development of stable recombinant non-pathogenic Marek's Disease virus (rMDVnp) vectors that encode and express antigens from multiple pathogens, specifically Infectious Laryngotracheitis Virus and Newcastle Disease Virus, using nonessential sites in the HVT genome, ensuring simultaneous protection against multiple diseases with a single vaccine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple monovalent rMDVnp constructs are used in alternative multivalent vaccines, then protection against multiple viral pathogens is intended, but one construct overgrows the other constructs preventing significant immune response
Solution Approach 1:
The patent combines multiple foreign genes from different viral pathogens (MDV1, ILTV, NDV) into a single recombinant rMDVnp construct rather than using multiple separate constructs. This merging approach ensures that all antigens are co-expressed from one vaccine vector, eliminating the overgrowth problem where one monovalent construct would dominate and prevent immune response to others.
Solution Approach 2:
The single rMDVnp construct is designed to express multiple foreign genes simultaneously, making it a universal vaccine that provides protection against multiple viral pathogens (Marek's disease, infectious laryngotracheitis, and Newcastle disease) through one immunization event, rather than requiring separate monovalent vaccines.
2Reliability
If recombinant viral constructs expressing pathogenic viral protein antigens are developed, then vaccine efficacy is improved, but vaccine complexity and manufacturing difficulty increase
Solution Approach 1:
The patent segments the vaccine design by using the rMDVnp vector as a separate, well-characterized backbone that can be independently produced and standardized. Foreign genes from different pathogens are inserted as modular expression cassettes into this stable vector framework, allowing the complex multivalent antigen expression to be achieved through controlled genetic engineering rather than creating entirely new complex viral constructs.
3Adaptability or versatility
If multiple vaccines are administered to chicks, then protection against multiple diseases is achieved, but the number of injections and stress on chicks increases
Solution Approach 1:
The patent merges multiple vaccine functions into a single injectable rMDVnp construct that expresses antigens from multiple viral pathogens. This consolidation reduces the number of separate injections required, decreasing stress on chicks and simplifying vaccination protocols while maintaining protection against Marek's disease, infectious laryngotracheitis, and Newcastle disease.
4Stability of the object's composition
If stable multivalent rMDVnp vectors are constructed, then vaccine stability is improved, but the complexity of construction and insertion site selection increases
Solution Approach 1:
The patent uses the rMDVnp vector itself as an intermediary platform that has been pre-validated for stability and safety. Rather than attempting to stabilize multiple separate monovalent constructs, the stability problem is solved by creating one well-characterized recombinant vector system that can accommodate multiple foreign genes through standardized insertion procedures, reducing the overall construction complexity.
Data Source
AI summary
Recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.